Skip to content
Peptides Codex
ENFR

Use the arrow keys to choose a result, Enter to open it, and Escape to close.

← Home
Peptide hormone (natriuretic peptide)

C-type natriuretic peptide

C-type natriuretic peptide (CNP) is a 22-residue peptide of the natriuretic family that acts locally rather than as a circulating natriuretic hormone.

By The Peptides Codex Editorial TeamIndividual review date not recorded

Page data last changed: . Chemistry registry snapshot: . Registry refreshes and identity assessments are separate from scientific content review.

Length
22 aa
Class
Peptide hormone (natriuretic peptide)
Function
Paracrine signaling via NPR-B; bone growth and vascular tone
Context
Endochondral growth and vascular physiology research

The paracrine member of the natriuretic family, driving long-bone growth through NPR-B.

Also known as: CNP · CNP-22 · NPPC

Part of the Foundational & therapeutic peptides cluster

Overview

C-type natriuretic peptide (CNP) is a 22-residue peptide of the natriuretic family that acts locally rather than as a circulating natriuretic hormone. Signaling through NPR-B and cGMP, it regulates endochondral bone growth, vascular tone and neuronal function. This page is educational and not medical advice.

Source & context

Biological / chemical source: Encoded by the NPPC gene (endothelium, cartilage, brain)

Primary research or clinical context: Endochondral growth and vascular physiology research

Distinct receptor and role

Unlike ANP and BNP, CNP is a selective agonist of natriuretic peptide receptor B (NPR-B) and lacks direct natriuretic activity. It is produced by endothelium, cartilage and the nervous system and functions in an autocrine/paracrine manner near its site of release.

Growth and vascular interest

CNP-NPR-B signaling is essential for growth-plate chondrocyte proliferation, which is why CNP analogs are studied in skeletal-dysplasia research. It also modulates vascular tone, gamete maturation and neuronal integrity, giving it a broad physiological footprint.

Sequence

One-letter sequence commonly cited for C-type natriuretic peptide (educational; isoforms and modifications may differ):

GLSKGCFGLKLDRIGSMSGLGC

GLSKGCFGLKLDRIGSMSGLGC

C-type natriuretic peptide22 aa · C93H157N27O28S3 · ≈ 2,197.6 DaPEPTIDESCODEX.COMN-terminus →→ C-terminusG1L2S3K+4G5C6F7G8L9K+10L11D−12R+13I14G15S16M17S18G19L20G21C22nonpolarpolaracidicbasicGly / Pronon-canonical (X)Hydropathy (Kyte–Doolittle): ▮ hydrophobic (cyan) / ▮ hydrophilic (rose) · Side-chain charge at pH 7: + / −
C-type natriuretic peptide — Structure cardDownload SVG
G1L2S3K4G5C6F7G8L9K10L11D12R13I14G15S16M17S18G19L20G21C22
Helical wheel projection

Residues plotted ~100° apart around an α-helix — clustering of one color reveals an amphipathic face.

Analyze sequences in the playground →

Structure & chemistry

Molecular identity & reference confidence

Source-supported reference

Reference values are taken from the cited molecular record or curated profile. A database match is not independent laboratory verification; modifications, counter-ions, and formulations can change the measured mass.

Molecular form
C-type natriuretic peptide (source record; form not independently established)
Species
Not established by this molecular identity audit
Termini (N / C)
Not specified / Not specified

Average reference mass

Reference policy updated: 2026-10-05

Molecular formula
C93H157N27O28S3
Average reference mass
≈ 2,197.6
Identifiers

Chemistry values: PubChem, IUPHAR/BPS Guide to Pharmacology · fetched 2026-10-01.

Clinical development snapshot

ClinicalTrials.gov lists 31 registered studies with “C-type natriuretic peptide” as an intervention (snapshot 2026-10-01). A registry footprint is not evidence of efficacy or approval.

Registered studies
31
Highest phase reached
Phase 3
Active in latest 100
12
Most recent update
2026-09-24
Most recently updated studies
NCTTitlePhaseStatusUpdated
NCT07441876Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With AchondroplasiaPhase 3recruiting2026-09-24
NCT06668805A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth HorPhase 2active not recruiting2026-09-23
NCT06849752Early Assessment and Initiation of GuideLine-Directed Evidence-Based Management-HF—recruiting2026-05-08
NCT04219007Vosoritide for Selected Genetic Causes of Short StaturePhase 2active not recruiting2026-03-18
NCT05492500A Study of Ponsegromab in People With Heart FailurePhase 2terminated2026-03-18
NCT03989947An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With AchondroplasiaPhase 2active not recruiting2026-03-13
See all on ClinicalTrials.gov →
Concentration math

C-type natriuretic peptide — reconstitution calculator

Enter how much peptide is in the vial and how much diluent (e.g. bacteriostatic water) is added. The tool returns the resulting solution concentration — and, for any amount you type, the volume it corresponds to. This is educational arithmetic, not a dosing recommendation.

Reference form: C-type natriuretic peptide (source record; form not independently established)Average reference mass: 2,197.6 Da

Syringe graduation
Solution concentration
5 mg/mL5,000 mcg/mL
mcg

Enter an amount to see the volume it corresponds to.

Educational concentration mathematics only. This tool does not recommend a dose, amount, or protocol, and nothing here is medical advice. Many peptides are not authorized by Health Canada for human use — see our reconstitution and bacteriostatic-water guides for context.

Open the C-type natriuretic peptide calculator on its own page →

FAQ about C-type natriuretic peptide

What is C-type natriuretic peptide?+

C-type natriuretic peptide (CNP) is a 22-residue peptide of the natriuretic family that acts locally rather than as a circulating natriuretic hormone. Signaling through NPR-B and cGMP, it regulates endochondral bone growth, vascular tone and neuronal function. This page is educational and not medical advice.

What Canadian product status is recorded for C-type natriuretic peptide?+

Canadian product status for C-type natriuretic peptide has not been verified in this profile. No verified record here does not mean no authorization exists. Status depends on the product, formulation and use; consult Health Canada's product records.

What is the typical length of C-type natriuretic peptide?+

C-type natriuretic peptide is commonly described as approximately 22 amino acids (Peptide hormone (natriuretic peptide)).

Related peptides

Motilin
Gut hormone
Motilin is a 22-amino-acid gut hormone secreted by endocrine cells of the small intestine. It coordinates the migrating motor complex, the wave of contractions that clears the digestive tract between meals, earning it the nickname the housekeeper of the gut.
Obestatin
Gut hormone
Obestatin is a 23-amino-acid peptide cleaved from the same preproghrelin precursor that produces ghrelin. It was originally proposed to oppose ghrelin's appetite-stimulating effects, though its physiology and receptor remain actively debated in the research literature.
Albiglutide
Incretin mimetic (GLP-1 receptor agonist)
Albiglutide is a GLP-1 receptor agonist created by genetically fusing two modified GLP-1 sequences to human serum albumin, giving it a long half-life suited to once-weekly dosing. Approved as Tanzeum and Eperzan in 2014, it was later withdrawn from the market for commercial reasons and is now a historical case study.
Neurotensin
Neuropeptide
Neurotensin is a 13-amino-acid neuropeptide found in the brain and gut. Research examines its interactions with dopamine signaling and its roles as a neuromodulator and local hormone.

References & further reading

  1. 1.Barr et al. (1996). C-type natriuretic peptide. Peptides
  2. 2.Sangaralingham et al. (2025). C-Type Natriuretic Peptide: Protecting the Aorta. Arterioscler Thromb Vasc Biol
  3. 3.Dickinson et al. (2024). C-type natriuretic peptide (CNP): The cardiovascular system and beyond. Pharmacol Ther
  4. 4.Lu et al. (2024). Modified C-type natriuretic peptide normalizes tumor vasculature, reinvigorates antitumor immunity, and improves solid tumor therapies. Sci Transl Med
  5. 5.Cabiati et al. (2021). C-type natriuretic peptide in childhood obesity. Peptides
  6. 6.Hirai et al. (2026). Collagen-binding C-type natriuretic peptide enhances chondrogenesis and osteogenesis. JCI Insight
  7. 7.Sangaralingham et al. (2020). C-type natriuretic peptide: the heart's guardian angel. Eur Heart J
  8. 8.Zheng et al. (2023). C-type natriuretic peptide (CNP) in the paraventricular nucleus-mediated renal sympatho-inhibition. Front Physiol
  9. 9.PMC — C-Type Natriuretic Peptide: a paracrine regulator in heart and vasculature
  10. 10.Wikipedia — Natriuretic peptide precursor C
Disclaimer: Educational content only. Not medical advice. Not instructions for human use. Research peptides and unapproved products may be restricted or illegal to market for human consumption in your jurisdiction. Consult qualified professionals and applicable law.
You might also like: All peptides · Atlas · Research · Tools
Cite this: Peptides Codex — C-type natriuretic peptide educational profile.
Tip: Use browser print (Ctrl/Cmd + P) for a clean PDF of this page.